Omalizumab is equally effective in persistent allergic oral corticosteroid-dependent asthma caused by either seasonal or perennial allergens

Omalizumab is marketed for chronic severe asthma patients who are allergic to perennial allergens. Our purpose was to investigate whether omalizumab is also effective in persistent severe asthma due to seasonal allergens. Thirty patients with oral corticosteroid-dependent asthma were treated with Om...

Descripción completa

Detalles Bibliográficos
Autores: Domingo, Christian|||0000-0001-8358-773X, Pomares, Xavier|||0000-0002-2783-414X, Navarro Giné, Albert|||0000-0001-7153-4673, Rudi, Núria, Sogo, Ana, Dávila, Ignacio|||0000-0001-8485-5513, Mirapeix Lucas, Rosa Maria|||0000-0001-9186-651X
Tipo de recurso: artículo
Fecha de publicación:2017
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:201648
Acceso en línea:https://ddd.uab.cat/record/201648
https://dx.doi.org/urn:doi:10.3390/ijms18030521
Access Level:acceso abierto
Palabra clave:Severe allergic asthma
Seasonal
Perennial
Omalizumab
Pathophysiology
id ES_b997794636cf8e0f201961a4e3facbbf
oai_identifier_str oai:ddd.uab.cat:201648
network_acronym_str ES
network_name_str España
repository_id_str
spelling Omalizumab is equally effective in persistent allergic oral corticosteroid-dependent asthma caused by either seasonal or perennial allergensA pilot studyDomingo, Christian|||0000-0001-8358-773XPomares, Xavier|||0000-0002-2783-414XNavarro Giné, Albert|||0000-0001-7153-4673Rudi, NúriaSogo, AnaDávila, Ignacio|||0000-0001-8485-5513Mirapeix Lucas, Rosa Maria|||0000-0001-9186-651XSevere allergic asthmaSeasonalPerennialOmalizumabPathophysiologyOmalizumab is marketed for chronic severe asthma patients who are allergic to perennial allergens. Our purpose was to investigate whether omalizumab is also effective in persistent severe asthma due to seasonal allergens. Thirty patients with oral corticosteroid-dependent asthma were treated with Omalizumab according to the dosing table. For each patient with asthma due to seasonal allergens, we recruited the next two consecutive patients with asthma due to perennial allergens. The dose of oral methyl prednisolone was tapered at a rate of 2 mg every two weeks after the start of treatment with omalizumab depending on tolerance. At each monthly visit, a forced spirometry and fractional exhaled nitric oxide (FeNO) measurement were performed and the accumulated monthly methyl prednisolone dose was calculated. At entry, there were no differences between groups in terms of gender, body mass index or obesity, year exacerbation rate, monthly dose of methyl-prednisolone (MP), FeNO and blood immunoglobuline E (IgE) MP, FeNO and IgE values, or spirometry (perennial: FVC: 76%; FEV: 62%; seasonal: FVC: 79%; FEV: 70%). The follow-up lasted 76 weeks. One patient in each group was considered a non-responder. Spirometry did not worsen in either group. There was a significant intragroup reduction in annual exacerbation rate and methyl prednisolone consumption but no differences were detected in the intergroup comparison. Omalizumab offered the same clinical benefits in the two cohorts regardless of whether the asthma was caused by a seasonal or a perennial allergen. These results strongly suggest that allergens are the trigger in chronic asthma but that it is the persistent exposure to IgE that causes the chronicity. 22017-01-0120172017-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/201648https://dx.doi.org/urn:doi:10.3390/ijms18030521reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2016482026-06-06T12:50:31Z
dc.title.none.fl_str_mv Omalizumab is equally effective in persistent allergic oral corticosteroid-dependent asthma caused by either seasonal or perennial allergens
A pilot study
title Omalizumab is equally effective in persistent allergic oral corticosteroid-dependent asthma caused by either seasonal or perennial allergens
spellingShingle Omalizumab is equally effective in persistent allergic oral corticosteroid-dependent asthma caused by either seasonal or perennial allergens
Domingo, Christian|||0000-0001-8358-773X
Severe allergic asthma
Seasonal
Perennial
Omalizumab
Pathophysiology
title_short Omalizumab is equally effective in persistent allergic oral corticosteroid-dependent asthma caused by either seasonal or perennial allergens
title_full Omalizumab is equally effective in persistent allergic oral corticosteroid-dependent asthma caused by either seasonal or perennial allergens
title_fullStr Omalizumab is equally effective in persistent allergic oral corticosteroid-dependent asthma caused by either seasonal or perennial allergens
title_full_unstemmed Omalizumab is equally effective in persistent allergic oral corticosteroid-dependent asthma caused by either seasonal or perennial allergens
title_sort Omalizumab is equally effective in persistent allergic oral corticosteroid-dependent asthma caused by either seasonal or perennial allergens
dc.creator.none.fl_str_mv Domingo, Christian|||0000-0001-8358-773X
Pomares, Xavier|||0000-0002-2783-414X
Navarro Giné, Albert|||0000-0001-7153-4673
Rudi, Núria
Sogo, Ana
Dávila, Ignacio|||0000-0001-8485-5513
Mirapeix Lucas, Rosa Maria|||0000-0001-9186-651X
author Domingo, Christian|||0000-0001-8358-773X
author_facet Domingo, Christian|||0000-0001-8358-773X
Pomares, Xavier|||0000-0002-2783-414X
Navarro Giné, Albert|||0000-0001-7153-4673
Rudi, Núria
Sogo, Ana
Dávila, Ignacio|||0000-0001-8485-5513
Mirapeix Lucas, Rosa Maria|||0000-0001-9186-651X
author_role author
author2 Pomares, Xavier|||0000-0002-2783-414X
Navarro Giné, Albert|||0000-0001-7153-4673
Rudi, Núria
Sogo, Ana
Dávila, Ignacio|||0000-0001-8485-5513
Mirapeix Lucas, Rosa Maria|||0000-0001-9186-651X
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Severe allergic asthma
Seasonal
Perennial
Omalizumab
Pathophysiology
topic Severe allergic asthma
Seasonal
Perennial
Omalizumab
Pathophysiology
description Omalizumab is marketed for chronic severe asthma patients who are allergic to perennial allergens. Our purpose was to investigate whether omalizumab is also effective in persistent severe asthma due to seasonal allergens. Thirty patients with oral corticosteroid-dependent asthma were treated with Omalizumab according to the dosing table. For each patient with asthma due to seasonal allergens, we recruited the next two consecutive patients with asthma due to perennial allergens. The dose of oral methyl prednisolone was tapered at a rate of 2 mg every two weeks after the start of treatment with omalizumab depending on tolerance. At each monthly visit, a forced spirometry and fractional exhaled nitric oxide (FeNO) measurement were performed and the accumulated monthly methyl prednisolone dose was calculated. At entry, there were no differences between groups in terms of gender, body mass index or obesity, year exacerbation rate, monthly dose of methyl-prednisolone (MP), FeNO and blood immunoglobuline E (IgE) MP, FeNO and IgE values, or spirometry (perennial: FVC: 76%; FEV: 62%; seasonal: FVC: 79%; FEV: 70%). The follow-up lasted 76 weeks. One patient in each group was considered a non-responder. Spirometry did not worsen in either group. There was a significant intragroup reduction in annual exacerbation rate and methyl prednisolone consumption but no differences were detected in the intergroup comparison. Omalizumab offered the same clinical benefits in the two cohorts regardless of whether the asthma was caused by a seasonal or a perennial allergen. These results strongly suggest that allergens are the trigger in chronic asthma but that it is the persistent exposure to IgE that causes the chronicity.
publishDate 2017
dc.date.none.fl_str_mv 2
2017-01-01
2017
2017-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/201648
https://dx.doi.org/urn:doi:10.3390/ijms18030521
url https://ddd.uab.cat/record/201648
https://dx.doi.org/urn:doi:10.3390/ijms18030521
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869417786034356224
score 15.301629

Similares en LA Referencia